Peyman Hosseinchi joined the T1D Fund in mid-February 2026. He brings experience in biotech company creation, investing in private and public biotech’s, and early-stage therapeutic strategy.

Prior to joining the Fund, Peyman was at Raven Venture (company creation arm of RA Capital), where he ideated new therapeutic concepts and led corporate development and strategy in portfolio companies. While at Raven, Peyman was a founding member of multiple NewCos across various therapeutic areas, including Stylus Medicine.

Earlier, Peyman was an Associate in RA Capital Management’s TechAtlas division, where he focused on investing in emerging therapeutic companies and providing strategic guidance for RA’s portfolio companies.

Peyman holds a PhD in Molecular Engineering from the University of Chicago and a dual B.S. in Mechanical & Aerospace Engineering from Sharif University of Technology in Tehran.

Lucio Iannone is a healthcare investor with more than 15 years of experience spanning venture capital, board leadership, and biotechnology. Prior to joining the T1D Fund, he served as Head of Health Investments at Leaps by Bayer, where he led the global investment team, shaped investment strategy, and directed deal execution across a portfolio with more than $1 billion in assets under management.

Lucio has served on the boards of over 18 companies. His scientific and investment background includes deep expertise in molecular biology, cell and gene therapy, and therapeutic innovation across oncology, autoimmune disease, and cardiovascular health.

Lucio earned his Ph.D. in Medicine from Imperial College London and is passionate about advancing novel therapeutics and supporting the next generation of transformative healthcare companies.